This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Zanamivir
From Proteopedia
Pharmacokinetics
| Neuraminidase Inhibitor Pharmacokinetics[1][2] | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | Zanamivir | Oseltamivir | |||||||||
| Tmax (hr) | 1.25 | 1.5 | |||||||||
| Cmax (ng/ml) | 31.6 | 57 | |||||||||
| Bioavailability (%) | 2 | 75 | |||||||||
| Protein Binding (%) | 10 | 42 | |||||||||
| T1/2 (hr) | 3 | 3.2 | |||||||||
| AUC (ng/ml/hr) | 185 | 204 | |||||||||
| Clearance (L/h) | 54.1 | 18.8 | |||||||||
| Dosage (mg) | 10 | 300 | |||||||||
| Metabolism | None | Hepatic | |||||||||
- ↑ A Randomized, Placebo Controlled, 3-Way Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir (RELENZA™) 10mg Administered Twice Daily for 5 Days by Rotacap/Rotahaler Compared to ROTADISK™/DISKHALER™ in Healthy Subjects, Study No: NAI113625, 2009
- ↑ Oo C, Hill G, Dorr A, Liu B, Boellner S, Ward P. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. Eur J Clin Pharmacol. 2003 Sep;59(5-6):411-5. Epub 2003 Aug 9. PMID:12910331 doi:http://dx.doi.org/10.1007/s00228-003-0639-6
